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Background: Guillain-Barre syndrome (GBS) is characterized by acute onset and progressive course, and is usually
associated with a good prognosis. However, there are forms of poor prognosis, needing ventilatory support and
major deficits at discharge. With this study we try to identify the factors associated with a worse outcome.
Methods: 106 cases of GBS admitted in our hospital between years 2000–2010 were reviewed. Epidemiological,
clinical, therapeutical and evolutionary data were collected.
Results: At admission 45% had severe deficits, percentage which improves throughout the evolution of the illness,
with full recovery or minor deficits in the 87% of patients at the first year review. Ages greater than 55 years,
severity at admission (p < 0.001), injured cranial nerves (p = 0.008) and the needing of ventilator support (p = 0.003)
were associated with greater sequels at the discharge and at the posterior reviews in the following months. 17%
required mechanical ventilation (MV). Values < 250 L/min in the Peak Flow-test are associated with an increased
likelihood of requiring MV (p < 0.001).
Conclusions: Older age, severe deficits at onset, injured cranial nerves, requiring MV, and axonal lesion patterns in
the NCS were demonstrated as poor prognostic factors. Peak Flow-test is a useful predictive factor of respiratory
failure by its easy management.
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The term Guillain-Barré syndrome (GBS) includes a set of
clinical syndromes (GBS) with a common pathophysio-
logical basis; an acute inflammatory polyneuropathy with an
autoimmune etiology [1-3]. Although usually characterized
by a progressive flaccid paralysis with areflexia a wide range
of motor, sensory and autonomic symptoms could be seen
[1-4]. In general, the diagnosis is based on clinical criteria
[4-7]; nevertheless, the presence of suggestive findings in
the complementary test as demyelinising changes in the
nerve conduction studies (NCS) or albuminocytological
dissociation in the cerebrospinal fluid (CSF), help to confirm
the diagnosis [1].
The worldwide incidence of GBS is reported to be 0.6-2.4
cases per 100,000 per year [8-15]. The classic form, the* Correspondence: igonsua@gmail.com
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distribution, and reproduction in any mediumacute inflammatory demyelinating polyradiculoneuropathy
(AIDP), is the most frequent subtype in Europe, which
accounts for 90% of GBS cases [2]. Other subtypes like the
axonal forms or the Miller-Fisher syndrome (MFS) [16,17]
are less common.
The prognosis is usually good, showing a complete
functional recovery or with minimal deficits in the 90%
of patients 1 year after the onset of illness [13,18].
Several factors have been identified as predictors of
poor outcome [13,14,19-21]. Death rate is described to be
between 1-18% [14,15]. This study aimed to describe the
epidemiological, clinical, laboratory, and electrodiagnostic
features, as well as to identify the predictive factors of
worse prognosis in the GBS or its subtypes.Methods
A retrospective review of the medical records of patients
admitted at La Paz University Hospital (Madrid, Spain)d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Epidemiological data of GBS patients










Upper respiratory infection 40 37.7










Mild (MRC 31–40) 60 56.6
Moderate (MRC 11–30) 43 40.6
Severe (MRC 0–10) 3 2.8
Cranial nerve involvement 37 35.5
Facial palsy uni/bilateral 27 25.5
MOE 14 13.2
Bulbar nerves 4 3.8
Ataxia 8 7,5
Other symptoms




Respiratory distress 18 17
GBS disability score
Minor signs or symptoms 12 11.3
Walk without support 41 38.7
Walk with support 16 15,1
Bedridden or chair bound 19 17.9
Ventilated 18 17
Death attributed to SGB 2 1.9
González-Suárez et al. BMC Neurology 2013, 13:95 Page 2 of 6
http://www.biomedcentral.com/1471-2377/13/95with the diagnosis of GBS between 2000–2010 was made.
106 fulfilled levels 1, 2 or 3 of diagnostic certainty for
GBS/MFS described by Sejvar et al. [7]. All demographic,
clinical, laboratory and electrophysiological data were
recorded, as well as outcome and treatment.
Severity at admission was assessed by the Medical
Research Council (MRC) sum score, valuing the strength
from 0 to 5 in 4 muscles (proximal and distal) in both
upper and lower limbs on both sides, so that the score
ranged from 40 (normal) to 0 (quadriplegic) and by the
GBS disability score advocated by Hughes et al. [22].
Cranial nerve involvement was considered separately by
the affectation of oculomotor, facial and bulbar nerves.
Respiratory weakness was assessed first by the value
obtained at the peak expiratory flow meter (Peak Flow), as
well as the need for mechanical ventilation throughout the
evolution. Sensory disturbances, autonomic alteration or
pain presence were also assessed.
Serological screening for preceding infections was
recorded, including Herpes Simplex virus (HSV), Varicella-
Zoster (VZV), cytomegalovirus (CMV), Epstein-Barr virus
(EBV), Mycoplasma Pneumoniae, B and C hepatitis virus,
Haemophilus Influenzae and, in selected cases, stool and
Campylobacter Jejuni determination. The CSF was analyzed
for cell count, glucose and protein concentration.
Neurophysiological studies were evaluated in accordance
with the criteria of Hadden et al. [23,24]. As in a retrospect-
ive study, not in all cases were the same nerves measured.
Also, electromyography studies (EMG) with concentric
needle electrodes were made to evaluate the axonal loss
(fibrillation, positive sharp wave…).
The evaluation of the functional impact was graded by
the GBS disability score [22] during the discharge from
the neurology or the rehabilitation department, and at the
third, sixth and twelfth month in the outpatient clinic.
The study was approved by the Research Ethics
Committee of La Paz Hospital, Madrid, Spain.
All statistical analyses were performed using the SPSS
12 for Windows program (Chicago, IL, E.U.A.). For
univariate analysis, Chi-square test for dichotomic
variables was used. For continuous variables, t-Student
test in parametric variables or U Mann-Withney with the
non-parametric ones were used.
Results
There was no difference between genders (ratio male/
female 1.07), with a mean onset age of 43.7 ± 23 years
(range 0–85). Demographic and clinical data are sum-
marized in Table 1. There was a seasonal rebound in
winter, when 41% of patients were diagnosed. Most
patients had an infectious antecedent preceding the onset
of the weakness, being the most frequent respiratory tract
infection (38%); at least 30% did not present a previous
infectious disease [25]. The mean of days since the start of
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12 ± 8.3 days (range 1–30).Clinical data
A motor disorder at the admission was referred in 94
patients, with a variable degree. By classifying them
according to the GBS disability score, 55% retained the
ability to walk (grades 1, 2 and 3), unlike the remaining
45% which showed a severe affectation (grades 4, 5 and
6); Respiratory distress was present in 17% of patients.
Pulmonary function was valued by the Peak Flow test in
50 patients, showed that values below 250 L/min were
associated with a greater likelihood of requiring MV during
the income (p < 0.05), independently of the presence of
uni/bilateral facial palsy (p < 0.05). Time between symptom
onset and admission was significantly lower in the severe
cases (mean 5.17 days) compared with the mild ones
(mean 8.87 days), so a faster progression could be postu-
lated in the first ones (p = 0.053). Non-motor symptoms
were described; the most frequent, neuropathic pain in
31% of patients, followed by sensory disturbances in 29%.
Autonomic dysfunctions were found in 8.5% of cases. In
7% of the patients a syndrome of inappropriate antidiuretic
hormone hypersecretion (SIADH) was diagnosed [26].Laboratory and neurophysiological findings
A lumbar puncture was made in 95 patients (90%) with an
average delay of 15 ± 11.71 days (range 1–80) since the
beginning of symptoms. Raised concentration of proteins
was present in 80 patients (85%) with albuminocytological
dissociation in 79 of them (85%).
Serologic studies were made in 101 patients (95%), in
8 (8%) cases CMV was the microorganism responsible
for the GBS; in 5 (5%) Mycoplasma Pneumoniae, in 1
(1%) EBV and 1 (1%) enterovirus; the remaining 85.1%
of serology was negative.Table 2 Neurophysiological data of patients with GBS
N CMAP (mV) MDL (ms) MC
Median 83 6,8 ± 5,6 6,4 ± 7,8 43,
Min-Max 0,07-21,30 0,1 ± 61,0 0,1
Ulnar 32 8,0 ± 7,8 3,4 ± 1,5 46,
Min-Max 0,1-16,6 0,1-7,5 0
Tibial post 14 4,8 ± 5,9 6,7 ± 2,2 33,
Min-Max 0,2-18,10 4,0-11,0 0,1
Peroneal 87 3,6 ± 3,9 6,9 ± 5,1 35,




Min-MaxNCS was made in 98 patients (92.5%) with a median
period from the onset to the neurophysiological study of
20.73 ± 10.17 days (range 2–62). Resumed data of the
neurophysiological test is shown in Table 2. In 57 (58%) a
demyelinating pattern was found, 7 (7%) an axonal pattern,
3 (3%) were unexcitable, 2 (2%) were normal, and 29 (30%)
didn’t fulfil diagnostic criteria for demyelinating lesion, but
changes consistent with a peripheral neuropathy were
present. Conduction blocks were present in 37 patients
(37.8%). F- Responses were altered (absent or delayed) in
29 of 64 median (45%), in 16 of 35 ulnar (46%) in 4 of 8
tibial (50%) and in 34 of 40 (85%) peroneal nerves. H-reflex
was affected in 26 of 48 (45%) cases evaluated. In sixth of
the Miller Fisher syndromes a NCS was made, 1 of them
(17%) was normal, and in the remaining 5 (83%) sensory
conduction was affected. In 3 of 5 (60%) H reflex was
absent. In the needle EMG examination signs of acute
denervation were present in 44 of 86 (51%).
The distribution of the different subtypes of GBS
was: AIDP in 83%, acute motor and sensory axonal
neuropathy (AMSAN) in 5.7%, acute motor axonal
neuropathy (AMAN) in 1.9%, MFS in 8.5% and cranial
multineuritis in 0.9%.
Treatment, outcome and prognosis
Some kind of treatment was offered to 89 patients
(84%): 88 received IVIg (83%) and 3 plasma exchange
(2.8%); in 2 patients both treatments were dispensed
sequentially. 16% of cases never started a treatment due to
the mild symptoms or the long evolution of the disease.
At discharge, absent or minor deficits were observed
in 38 patients (36%), 30 (28%) were able to walk for 10
meters without a help, 28 (26%) needed assistance to walk,
7 (7%) were bedridden and 1 (1%) needed respiratory
support. Two patients died of the disease. Patients
were followed in the outpatient clinic at 3, 6 and
12 months (Table 3).V (m/s) n SNAP (μV) DL(ms) SCV (m/s)
6 ± 17,9 85 7,03 ± 7,8 3,2 ± 3,4 43,6 ± 16,6
0 ± 65,5 0,1-43,2 0,1-27,7 0,1-63,4
6 ± 17,4 72 3,9 ± 3,9 2,6 ± 1,9 43,2 ± 16,4





71 6,01 ± 5,4 2,6 ± 1,9 39,2 ± 15,5
0,1-27,4 0,1-18,0 0,1-57,2
39 9,7 ± 8,2 2,2 ± 0,7 39,8 ± 12,7
0,1-37,4 0,1-3,8 0,13-8
Table 3 Proportion of patients, based on the GBS score, during the follow-up
Discharge 3th month revision 6th month revision 12th month revision
N (%) N (%) N (%) N (%)
Healthy 4 3,8 18 29,5 17 36,2 18 58,1
Minor deficits or symptoms 34 32,1 19 31,1 15 31,9 7 22,6
Walk without support 30 28,3 14 23 8 17 2 6,5
Walk with support 28 26,4 10 16,4 7 14,9 4 12,9
Bedbridden or chairbound 7 6,6 0 0 0
Ventilated 1 0,9 0 0 0
Death 2 1,9 0 0 0
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poor outcome: 1) patients with ages greater than 55 years
were most affected at the admission (p = 0.027), with
greater deficits at discharge (p = 0.2) and at the third
(p = 0.1), sixth (p = 0.001) and twelfth month (p = 0.006); 2)
severity at admission, score based on the GBS disability
scale (disabling or non-disabling), was also associated with
more disability at discharge (p < 0.001), and at the succes-
sive medical reviews at the third (p = 0.001) and the sixth
month (p < 0.001); 3) cranial nerve involvement was related
with greater deficits at discharge (p = 0.008) and 4) mech-
anical ventilation requirement showed greater sequels at
discharge (p = 0.003), in the follow up the results were not
statistically significant but a trend to associate with greater
deficits was seen. Finally, there seems to be a trend towards
a worse prognosis in those patients with axonal lesions
in the conduction studies (p = 0.2) which is likely to
be maintained throughout the evolution (Table 4).
Discussion
The present work has the limitations of a retrospective
study based on hospital case-mix. The incidence is reportedTable 4 Possible predictor factors of a poor outcome
Discharge deficits 3th month revision de
Disabling p Disabling
Severity at admission <0.001 0.
Non disabling 11.3% (6/53) 20.6% (7/34)
Disabling 60.3% (32/53) 63% (17/27)
Age 0.2 0
<55 years 31.3% (21/67) 34.1% (15/44)
>55 years 43.6% (17/39) 52.9% (9/17)
MV 0.003 0
Yes 66.7% (12/18) 66.7% (6/9)
No 29.5% (26/88) 34.6% (18/52)
Axonal lesion at CNS 0.2 0
Demyelinating 40.7% (22/54) 43.3% (13/30)
Axonal 71.4% (5/7) 66,7% (4/6)
Statistical analysis of the disabling deficits and the possible poor prognostic factorsto be 0.6-2.4 cases per 100,000 per year [18,19,21]. Changes
suffered in the last years in the attendance area of the hos-
pital make incidence calculation complex and inaccurate;
however, it appears to be of 1.68-2.46 per 100,000 per year.
There is no difference between gender [1,2]. The bimodal
shape wasn’t present in our study [8-10], as there is a linear
increase in the incidence with age [1,2,9,11,12,24]. GBS is
considered a sporadic illness, without a seasonal cluster
[1,9]; however, a trend to accrue in winter is shown in our
series [11,12]. The infectious event is described to appear
in 40-70% of patients [1-3,8-12]. In our series up to 70% of
cases have had one, of which respiratory infection was the
most frequent.
As in previous series, weakness and hypo/areflexia were
the most frequent symptoms, followed by neuropathic
pain and numbness. Hyponatremia, as a symptom of
SIADH is not a classical manifestation of GBS; however,
there are series in which are described to be present
in up to 58% of the cases; in our review, it was found
in 7% of our patients.
There isn’t a consensus about the neurophysiological
values defining GBS and its variants [2,4,5,7,23,24,26-29].ficits 6th month revision deficits 12th month revision deficits
p Disabling p Disabling p
001 <0.001 0.2
7.7% (2/26) 11.8% (2/17)
61.9% (13/21) 28.6% (4/14)
.17 0.01 0.006
17.6% (6/34) 8% (2/25)
69.2% (9/13) 66.7% (4/69
.13 0.6 1
42.9% (3/7) 25% (1/4)
30% (12/40) 18.5% (5/27)
.3 0.06 0.4
30.4% (7/23) 16,7% (3/18)
80% (4/5) 33.3% (1/3)
during the follow-up.
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duction velocity (MCV) decrease, prolongation of motor
distal latency, conduction blocks, temporal dispersion and
increased F-wave latency [27]. It is reported that the first
electromyographic changes are the alteration of F-wave
and H-reflex response [2,22], altered both in our NCS
reported as normal, probably due to the earliness of the
exploration. In MFS, the CNS are normal in most cases;
nonetheless, discrete changes in the sensory conduction
or in H-reflex may be present [30-32], some authors
postulate a damage in the afferent proprioceptive system
as a pathophysiological basis [32].
As classically described, in our study illness prognosis
is favourable; 81% of patients presented absent or minimum
neurological deficits one year after the onset. Older age,
illness severity in the acute phase, prior gastrointestinal
infection and axonal injury in the CNS and mechanical
ventilation requirement [15,20,33,34] are among the fac-
tors that have been advocated for poor prognosis. Van
Koningsveld et al. defined a clinical prognostic scoring
system for GBS outcome at 6 months, the “Erasmus GBS
Outcome Score” or EGOS [15], it was based on the punc-
tuation on the GBS disability score at 2 weeks from the
admission, the history of diarrhoea and the age. Recently,
Walgaard et al. have validated a modified EGOS
(mEGOS) with the main difference being the use of the
MRC sum score at admission and in the 7th day instead
the GBS disability score [35], they claimed that the MRC
sum score is more accurate, and the possibility of being
used at admission could predict the future treatments.
However, the mEGOS made on the 7th day after the
admission show increased predictive value instead the one
made on the first day [35]. However, although useful, the
mEGOS passed on the first day of admission showed
lower predictive ability than the one performed on
the 7th day. In our study we demonstrate that, even
in the first day of admission, lower scores on the GBS
scale are associated with worse outcome and greater
disability at discharge, 3 and 6 months. Respiratory
distress is the leading cause of death in the acute
phase, 20-30% requiring ventilatory support [20]. Many
factors have been proposed as predictors of the future
need for respiratory support, like forced vital capacity
(FVC) < 60%, bulbar dysfunction, rapid progression of the
illness, and difficulty raising the head [19,20]. Van Doorn
et al. propose a regularly monitoring of the respiratory
function initially every 2-4 h, and then every 6-12 h [1].
Although FVC is considered to be the gold standard
test for detecting impaired ventilation it has some
disadvantages, the requirement of portable spirometers in
the acute phase due to the instability of the patient, the
need for a minimum of preparation and knowledge of
the technique by medical personnel and the higher
cost. Suárez et al. describe a serie of 79 patients withneuromuscular diseases in which the Peak Flow test
proved to be useful in the monitoring of expiratory
muscle weakness [35]. In our hospital, patients were
monitored by the Peak Flow test each 6 hours in the acute
phase, being observed that values below 250 L/min predict
the posterior need of respiratory support (p < 0.05),
independently of the presence of facial palsy that
could hinder the use of the test (p < 0.05), making the
Peak Flow a safe, inexpensive, and widely-available test in
the monitoring of patients with GBS.
Conclusion
Our series is in concordance with those previously
published. The seasonal cluster in winter is worth
noting on which there is a great controversy. Regarding
the outcome, our series reported a worse prognosis in
patients with older age, severe deficits at the beginning,
injured cranial nerves, requiring MV, and axonal lesion
patterns in the NCS. Finally, project the Peak Flow-test as
a useful predictive factor of respiratory failure by its
availability, and easy management.
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